title: An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat.
abstract: Paclitaxel (Taxol) is a frontline antineoplastic agent used to treat a variety of solid tumors including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime. To begin to understand the cellular events that contribute to this neuropathy, we examined a marker of cell injury/regeneration (activating transcription factor 3; ATF3), macrophage hyperplasia/hypertrophy; satellite cell hypertrophy in the dorsal root ganglia (DRG) and sciatic nerve as well as astrocyte and microglial activation within the spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses of paclitaxel. At day 1 post-infusion, there was an up-regulation of ATF3 in a subpopulation of large and small DRG neurons and this up-regulation was present through day 10. In contrast, hypertrophy of DRG satellite cells, hypertrophy and hyperplasia of CD68(+) macrophages in the DRG and sciatic nerve, ATF3 expression in S100beta(+) Schwann cells and increased expression of the microglial marker (CD11b) and the astrocyte marker glial fibrillary acidic protein (GFAP) in the spinal cord were not observed until day 6 post-infusion. The present results demonstrate that using the time points and markers examined, DRG neurons show the first sign of injury which is followed days later by other neuropathological changes in the DRG, peripheral nerve and dorsal horn of the spinal cord. Understanding the cellular changes that generate and maintain this neuropathy may allow the development of mechanism-based therapies to attenuate or block this frequently painful and debilitating condition.
authors: Department of Diagnostic & Biological Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
authors: Christopher M
authors: CM
authors: Peters
authors: Juan Miguel
authors: JM
authors: Jimenez-Andrade
authors: Michael A
authors: MA
authors: Kuskowski
authors: Joseph R
authors: JR
authors: Ghilardi
authors: Patrick W
authors: PW
authors: Mantyh
mesh_terms: D051700:Activating Transcription Factor 3 / Q000378:metabolism; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001253:Astrocytes / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D005727:Ganglia, Spinal / Q000187:drug effects* / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007276:Injections, Intraventricular / Q000379:methods; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D008297:Male; D008954:Models, Biological; D017239:Paclitaxel / Q000008:administration & dosage*; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects* / Q000473:pathology; D013116:Spinal Cord / Q000187:drug effects* / Q000473:pathology; D018709:Statistics, Nonparametric; D013997:Time Factors; D000097382:CD68 Molecule
chemical_list: D051700:Activating Transcription Factor 3; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000972:Antineoplastic Agents, Phytogenic; D005904:Glial Fibrillary Acidic Protein; D017239:Paclitaxel; D010751:Phosphopyruvate Hydratase; C497108:Atf3 protein, rat; C067980:CD68 antigen, human; D000097382:CD68 Molecule
references: Ann Oncol. 1995 May;6(5):489-94
references: 7669713
references: Eur J Cancer. 2005 Jul;41(10):1460-6
references: 15913989
references: Exp Neurol. 1996 Sep;141(1):94-101
references: 8797671
references: J Comp Neurol. 1997 Mar 17;379(3):428-42
references: 9067834
references: Pain. 1997 Feb;69(3):317-22
references: 9085307
references: Ann Neurol. 1998 Jan;43(1):46-55
references: 9450768
references: Neuropathol Appl Neurobiol. 1999 Feb;25(1):29-40
references: 10194773
references: Eur J Neurosci. 1999 May;11(5):1711-22
references: 10215925
references: J Neurosci Res. 1999 Oct 1;58(1):33-41
references: 10491570
references: Trends Neurosci. 2005 Feb;28(2):101-7
references: 15667933
references: Exp Neurol. 2005 May;193(1):85-100
references: 15817267
references: Eur J Cancer. 2006 Jan;42(1):24-30
references: 16293411
references: Acta Neuropathol. 1999 Dec;98(6):651-3
references: 10603043
references: Mol Cell Neurosci. 2000 Feb;15(2):170-82
references: 10673325
references: Neurotoxicology. 2000 Jun;21(3):389-93
references: 10894128
references: Pain. 2000 Dec 1;88(3):239-48
references: 11068111
references: Pain. 2001 Apr;91(3):351-60
references: 11275393
references: Trends Neurosci. 2001 Aug;24(8):450-5
references: 11476884
references: Eur J Neurosci. 2002 Mar;15(6):1037-47
references: 11918652
references: J Neurol. 2002 Jan;249(1):9-17
references: 11954874
references: Neuroscience. 2002;112(1):23-38
references: 12044469
references: J Neurosci. 2002 Aug 1;22(15):6696-703
references: 12151548
references: Pain. 2003 Jan;101(1-2):65-77
references: 12507701
references: Lab Invest. 2003 Feb;83(2):175-85
references: 12594233
references: J Neurosci. 2003 May 15;23(10):4017-22
references: 12764087
references: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7947-52
references: 12808141
references: Nature. 2003 Aug 14;424(6950):778-83
references: 12917686
references: Neuroscience. 2003;121(3):691-704
references: 14568029
references: Neuroscience. 2003;121(3):815-24
references: 14568039
references: Brain. 2004 Mar;127(Pt 3):671-9
references: 14761904
references: Eur J Neurosci. 2004 Mar;19(6):1437-45
references: 15066140
references: Pain. 2004 May;109(1-2):132-42
references: 15082135
references: Brain Res. 1982 Feb 25;234(2):309-17
references: 7059833
references: J Neurocytol. 1984 Apr;13(2):187-200
references: 6726286
references: J Neurocytol. 1984 Dec;13(6):923-34
references: 6398831
references: Proc Natl Acad Sci U S A. 1986 Jun;83(11):4094-8
references: 3012551
references: J Comp Neurol. 1987 Jun 8;260(2):246-55
references: 3038969
references: Nature. 1987 Dec 17-23;330(6149):658-9
references: 3317065
references: J Comp Neurol. 1987 Dec 8;266(2):183-97
references: 2830320
references: J Comp Neurol. 1988 Sep 15;275(3):460-8
references: 3225349
references: Neurosci Lett. 1989 Mar 13;98(1):8-12
references: 2710403
references: Peptides. 1990 Jul-Aug;11(4):719-28
references: 1978300
references: J Cell Biol. 1992 Oct;119(1):45-54
references: 1527172
references: Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15
references: 8102012
references: Arch Neurol. 1994 Jul;51(7):726-9
references: 7912506
references: Exp Neurol. 1994 Oct;129(2):237-43
references: 7957738
references: J Neurocytol. 1994 Sep;23(9):515-31
references: 7815085
references: Immunology. 1994 Sep;83(1):140-7
references: 7821959
references: Exp Neurol. 1995 Jan;131(1):11-22
references: 7895805
references: Exp Neurol. 1995 May;133(1):64-72
references: 7601264
references: J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81
references: 7616600
references: Eur J Neurosci. 2006 Jan;23(2):365-73
references: 16420444
references: BMC Cancer. 2006;6:5
references: 16398939
references: J Natl Cancer Inst. 2006 Mar 15;98(6):382-8
references: 16537830
references: J Clin Oncol. 2006 Apr 1;24(10):1633-42
references: 16575015
references: Anticancer Res. 2006 Mar-Apr;26(2A):1065-70
references: 16619507
references: Mol Cell Neurosci. 2006 May-Jun;32(1-2):143-54
references: 16713293
references: Neurosci Lett. 2006 Sep 11;405(1-2):62-7
references: 16854522
references: Nat Rev Neurosci. 2006 Oct;7(10):797-809
references: 16988655
references: Neuroscience. 2006 Oct 27;142(3):809-22
references: 16887276
references: Exp Neurol. 2007 Jan;203(1):42-54
references: 17005179
references: Brain Res Brain Res Rev. 2005 Jun;48(3):457-76
references: 15914252
references: Neuroreport. 1996 Mar 22;7(4):857-60
references: 8724660